ARL conducts secondary screens for lead generation, comprising kinetics studies (compound mechanism of action), hit assessment, lead optimization and candidate selection. ARL has established a network of strategic partnerships with other reputable CROs for computer-based drug design (CADD), high-throughput primary screening, medicinal chemistry, pre-clinical pharmacology and toxicology studies to complement our core competencies in early-stage translational R&D.